PEAK PHARMACEUTICALS, INC.: 10-Q filed 2023-02-09
What PEAK PHARMACEUTICALS, INC. reported in its quarterly report filed 2023-02-09 (fiscal Q1 2023): 16 published measures, 33 facts as tagged in accession 0001199835-23-000089.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-02-09
- Fiscal period
- fiscal Q1 2023
- Accession
- 0001199835-23-000089 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PEAK PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 102,480 | USD | |
| At 2022-09-30 | 130,349 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 705,876 | USD | |
| At 2022-09-30 | 621,503 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | -603,396 | USD | |
| At 2022-09-30 | -491,154 | USD | |
| At 2021-12-31 | -385,540 | USD | |
| At 2021-09-30 | -326,185 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | -112,242 | USD | 92 |
| 2021-10-01 to 2021-12-31 | -59,355 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | -30,879 | USD | 92 |
| 2021-10-01 to 2021-12-31 | -43,598 | USD | 92 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | -30,000 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | -5,466,798 | USD | |
| At 2022-09-30 | -5,354,556 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | -110,412 | USD | 92 |
| 2021-10-01 to 2021-12-31 | -52,063 | USD | 92 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | 1,830 | USD | 92 |
| 2021-10-01 to 2021-12-31 | 8,831 | USD | 92 |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 307,146 | USD | |
| At 2022-09-30 | 224,548 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | 110,412 | USD | 92 |
| 2021-10-01 to 2021-12-31 | 52,063 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 78,363,567 | shares | |
| At 2022-09-30 | 78,363,567 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 4,855,566 | USD | |
| At 2022-09-30 | 4,855,566 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 125,730 | USD | |
| At 2022-09-30 | 123,955 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | 110,412 | USD | 92 |
| 2021-10-01 to 2021-12-31 | 52,063 | USD | 92 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2022-12-31 | 36,586 | USD | 92 |
| 2021-10-01 to 2021-12-31 | -6,216 | USD | 92 |
Inspect the source
- Entity
- PEAK PHARMACEUTICALS, INC. / CIK 0001452804
- Captured
- 2026-09-20T09:05:40.595Z
- SEC response SHA-256
3fd5eb06bfdebffa42021b094c4c379c1efd3c7143204265bf035090db070211
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001452804.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))